Elevation Oncology Inc (ELEV) - Total Liabilities
Based on the latest financial reports, Elevation Oncology Inc (ELEV) has total liabilities worth $35.49 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Elevation Oncology Inc to evaluate the company's liquid asset resilience ratio.
Elevation Oncology Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Elevation Oncology Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Elevation Oncology Inc assets under control.
Elevation Oncology Inc Competitors by Total Liabilities
The table below lists competitors of Elevation Oncology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wenzhou Kangning Hospital Co. Ltd
F:4WK
|
Germany | €1.71 Billion |
|
Signet Industries Limited
NSE:SIGIND
|
India | Rs7.13 Billion |
|
Blossom M&C Co. Ltd
KQ:263920
|
Korea | ₩19.82 Billion |
|
APPIA RARE EARTH+U O.N.
F:A0I0
|
Germany | €3.85 Million |
|
DAP Corporation
KQ:066900
|
Korea | ₩135.71 Billion |
|
Point Mobile Co. Ltd
KQ:318020
|
Korea | ₩43.69 Billion |
|
TMK Energy Ltd
AU:TMK
|
Australia | AU$532.78K |
|
Hermana Holding ASA
OL:HERMA
|
Norway | Nkr700.00K |
Liability Composition Analysis (2019–2024)
This chart breaks down Elevation Oncology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Elevation Oncology Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Elevation Oncology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Elevation Oncology Inc (2019–2024)
The table below shows the annual total liabilities of Elevation Oncology Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $35.60 Million | +3.85% |
| 2023-12-31 | $34.28 Million | -24.04% |
| 2022-12-31 | $45.13 Million | +413.00% |
| 2021-12-31 | $8.80 Million | -91.54% |
| 2020-12-31 | $103.99 Million | +1235.41% |
| 2019-12-31 | $7.79 Million | -- |
About Elevation Oncology Inc
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable link… Read more